Introduction
Stem cell research (SCR) has been the subject of many controversies over the past few decades. Studies have shown that the exploration of the options that SCR provides may lead to the creation of the cure for diseases such as cardiovascular (CVD) health issues, Parkinson’s disease, Alzheimer’s disease, and diabetes, to name just a few (Zhang et al. 85). Therefore, despite possible ethical concerns associated with the implications of SCR on human nature, I believe that the use of embryonic cells as one of the key aspects of CSR should be promoted as a possible source for solutions for numerous diseases and disorders.
Main body
The use of embryo cells in SCR opens various possibilities for addressing some of the most complex health issues, which means that the research has to be supported. SCR, in general, and the use of embryonic cells, in particular, are likely to have huge positive implications for healthcare and the management of diseases such as CVD, Parkinson’s, and Alzheimer’s (“Chapter 9 – Cell Communication”). Although the opponents of SCR may claim that it implies playing God and tampering with human nature, the positive outcomes that SCR may have should be explored and used to their full potential.
Conclusion
Due to the potential in managing the diseases and disorders that are presently deemed as incurable, I am certain that CSR should be continued despite the ethical concerns that it raises. Since the possible positive outcomes outweigh the ostensible negative implications, the research should continue, with a greater focus on the treatment opportunities that the utilization of embryonic cells provides. Despite the fact that the use of the specified material may be seen as challenging to the concept of morality and the current social norms, the treatment opportunities that it potentially has been tremendous. Thus, the opportunity described above should not be missed.
Works Cited
“Chapter 9 – Cell Communication.” Georgia Highlands College, n.d. Web.
Zhang, Qingxi, et al. “Stem Cells for Modeling and Therapy of Parkinson’s Disease.” Human Gene Therapy, vol. 28, no. 1, 2017, pp. 85-98.